KLRS — Kalaris Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $109.04m
- -$9.25m
- 42
- 33
- 44
- 34
Annual income statement for Kalaris Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 71.3 | 170 | 171 | 200 | 65.4 |
| Operating Profit | -71.3 | -170 | -171 | -200 | -65.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -69.8 | -171 | -169 | -191 | -58.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -69.8 | -172 | -169 | -190 | -58.8 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -69.8 | -172 | -169 | -190 | -58.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -69.8 | -172 | -169 | -190 | -58.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.13 | -2.74 | -2.2 | -1.71 | -9.7 |